

From: [Seville, Tyler](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [Fitzsimmons, Tricia](#)
Subject: VT Notice of Introduction of New High-Cost Prescription Drugs - Kesimpta
Date: Friday, August 21, 2020 5:32:10 PM

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

To the Office of Attorney General:

Pursuant to 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs), effective July 1, 2018, when a prescription drug manufacturer introduces a new prescription drug to market at a wholesale acquisition price above the threshold set for a specialty drug under the Medicare Part D program, that manufacturer is required to provide certain written information to the Attorney General's Office.

Per section (2)(b) of § 4637 Notice Of Introduction Of New High-Cost Prescription Drugs, Novartis is notifying the Office of the Attorney General in the state of Vermont the Wholesaler Acquisition Cost (WAC) within 3 calendar days following the release of Kesimpta® into the commercial market.

Please see table below:

NDC	Drug Product Description	Introduction to Market	WAC at Introduction
00078-1007-68	Kesimpta (Ofatumumab) 20mg/0.4mL (auto injector)	August 21, 2020	\$ 6,916.67

Please feel free to contact me if you have any questions and/or require any additional information.

Regards,
Tyler

Tyler Seville
Associate Director, Policy Reporting
Tyler.seville@novartis.com

Novartis Services, Inc.
North America Public Affairs
One Health Plaza
Building 200, Office 720
East Hanover, NJ 07936-1080
USA